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 Introduction 
 Almost 20 years ago, the Radiation Therapy Oncology 
Group (RTOG) 8501 trial defined concomitant chemora-
diation (CRT) as the standard of care for locally advanced 
esophageal cancer  [1–3] . Patients treated with 50.0 Gy 
concurrently with two parallel and two adjuvant cycles of 
cisplatin and 5-fluorouracil (5-FU) reached a 26% 5-year 
overall survival (OS)  [2] . Since then, technical and proce-
dural treatment options have considerably evolved  [4, 5] . 
However, the results of the original RTOG trial (arm B) 
have not been prospectively exceeded, and today, the op-
timal arrangement of CRT remains debatable.
 Particular uncertainty concerns the optimal radiation 
(RT) dose within the concept of definitive CRT. Although 
the INT 0123 trial did not provide evidence of survival 
benefits by a boost dose to 64.8 Gy versus standard 50.4 
Gy  [6] , today, most centers routinely escalate the doses to 
 1 50.0 Gy. Accordingly, prospective trials on definitive 
 Key Words 
 Esophageal cancer   Chemoradiation   
Radiochemotherapy   Radiotherapy   Surgery 
 Abstract 
 Objectives: It was the aim of this study to assess our institu-
tional experience with definitive chemoradiation (CRT) ver-
sus induction chemotherapy followed by CRT with or with-
out surgery (C-CRT/S) in esophageal cancer.  Methods: We 
retrospectively analyzed 129 institutional patients with lo-
cally advanced esophageal cancer who had been treated by 
either CRT in analogy to the RTOG 8501 trial (n = 78) or C-
CRT/S (n = 51).  Results: The median, 2- and 5-year overall 
survival (OS) of the entire collective was 17.6 months, 42 and 
24%, respectively, without a significant difference between 
the CRT and C-CRT/S groups. In C-CRT/S patients, surgery 
 statistically improved the locoregional control (LRC) rates
(2-year LRC 73.6 vs. 21.2%; p = 0.003); however, this was 
 translated only into a trend towards improved OS (p = 0.084). 
The impact of escalated radiation doses ( 6 60.0 vs.  ! 60.0 Gy) 
on LRC was detectable only in T1–3 N0–1 M0 patients of the 
CRT group (2-year LRC 77.8 vs. 42.3%; p = 0.036).  Conclusion: 
Definitive CRT and a trimodality approach including surgery 
(C-CRT/S) had a comparable outcome in this unselected pa-
 Received: September 9, 2011 
 Accepted after revision: November 21, 2011 
 Published online: January 20, 2012 
Oncology 
 Dr. Bernhard Berger  
 Department of Radiation Oncology, University of Tuebingen  
 Hoppe-Seyler-Strasse 3 
 DE–72076 Tuebingen (Germany) 
 Tel. +49 7071 29 85972, E-Mail bernhard.berger   @   med.uni-tuebingen.de  
 © 2012 S. Karger AG, Basel
0030–2414/11/0816–0387$38.00/0 
 Accessible online at:
www.karger.com/ocl 
 Berger  /Stahlberg  /Lemminger  /Bleif  /
Belka  /Bamberg  
Oncology 2011;81:387–394388
versus neoadjuvant CRT have shown the safety of  6 60.0 
Gy during definitive CRT  [7, 8] . However, a standardized 
dose escalation during RTOG 8501 analog CRT has not 
been validated so far.
 If surgery is included into a multimodal approach to 
esophageal cancer, the variability of treatment options is 
even higher. Neoadjuvant CRT followed by surgery (tri-
modality treatment) has been randomized prospectively 
against definitive CRT in at least two large trials  [7, 8] . Al-
though differing in treatment schedule and design, both 
studies confirmed the lack of a survival benefit by surgery, 
particularly in patients who respond to induction CRT. 
The inclusion of surgery led to improved locoregional 
control (LRC) rates; however, perioperative morbidity 
hampered its translation into improved OS. Thus, as a 
matter of principle, a non-surgical approach to esophageal 
cancer is not inferior to trimodality treatment  [4, 9] .
 The CRT regimen applied in the two above-mentioned 
trials  [7, 8] differed from the standard as set by arm B of 
the RTOG 8501 study: whereas RT was mainly performed 
as split-course hypofractionated treatment in the French 
study (2  ! 15.0 Gy)  [7] , the German trial scheduled
induction chemotherapy with cisplatin, etoposide and 
5-FU followed by CRT in standard fractionation (40.0 
Gy) concomitant to cisplatin and etoposide  [8] . Likewise, 
several institutional reviews reported on differing CRT 
regimens with or without surgery  [10–12] . 
 In light of the broad spectrum of CRT regimens used 
for multimodal treatment of esophageal cancer, we retro-
spectively analyzed our own institutional experience 
which was rather strictly oriented towards the concept of 
the RTOG 8501 trial (CRT group) and the German phase 
III trial on trimodality treatment versus definitive CRT 
(C-CRT/S group), respectively  [8] .
 Patients and Methods 
 Treatment Protocol 
 Between 1999 and 2009, 149 patients with primary or recur-
rent non-metastatic esophageal cancer underwent treatment at 
the Department of Radiation Oncology, University of Tübingen. 
The present analysis was limited to patients who received defini-
tive CRT (CRT group, n = 78) or inductive chemotherapy followed 
by CRT with or without surgery (C-CRT/S group, n = 51). All pa-
tients had a biopsy-proven squamous cell carcinoma or adenocar-
cinoma of the cervical, thoracic or distal esophagus classified as 
T1–4 N0–1 M0–1a according to the 6.0 TNM criteria. A total of 
129 patients met the research criteria and were systematically re-
viewed for the following data: patient demographics, tumor stage, 
histology, treatment details and performance, toxicity, treatment 
outcome and follow-up.
 Definitive CRT was performed according to arm B of the 
RTOG 8501 trial  [1] delivering 50.0 Gy with two concomitant and 
two adjuvant cycles of cisplatin (75 mg/m 2 on day 1) and 5-FU 
(1,000 mg/m 2 on days 1–4). However, in contrast to the 50.0-Gy 
end dose of the RTOG trial, the RT doses were individually esca-
lated in most patients with respect to tumor localization and size, 
patient performance and treatment tolerability (median boost 
dose 10.0 Gy). For RT, we routinely used a computed tomography-
based 3D conformal technique or intensity-modulated radiother-
apy. The target volume delineation was based on the Internation-
al Commission on Radiation Units and Measurements 50 defini-
tions and followed the treatment conditions of contemporary 
trials on esophageal cancer  [6, 8, 13] .
 Trimodality treatment (C-CRT/S) was analogized to the Ger-
man multicenter trial on neoadjuvant chemotherapy/CRT plus 
surgery versus definitive CRT, with 10 of 51 patients being ran-
domized in the original study  [8] . Treatment consisted of induc-
tive chemotherapy with three courses of cisplatin, etoposide and 
5-FU/leucovorin, followed by CRT (30.0–40.0 Gy with concomi-
tant cisplatin on days 2 and 8, etoposide on days 3–5). After re-
staging, the patients were allocated individually to either surgery 
or boost RT (60.0- to 65.0-Gy end dose) reflecting the initial tu-
mor localization and size (surgical accessability), the restaging 
results, medical fitness and the patient’s preference.
 Statictical Analysis 
 The main endpoint of this intent-to-treat analysis was to deter-
mine OS, LRC and distant control (DC) rates. The survival out-
come was calculated using the Kaplan-Meier method with OS, 
LRC and DC being assessed from the first day of treatment until 
locoregional recurrence or progress, appearance of distant metas-
tases, and death from any cause, respectively. To compare surviv-
al data, the Mantel-Cox log-rank test was used (p values  ^  0.05 
were considered significant). Patient and treatment characteristics 
were compared using a two-sided Mann-Whitney U test for con-
tinuous variables and Fisher’s exact test for categorical variables, 
respectively. Secondary objectives of this analysis were response 
and toxicity evaluation as well as identification of pretreatment 
and treatment-related prognostic factors. The treatment outcome 
was assessed according to the Response Evaluation Criteria in Sol-
id Tumors (RECIST) by endoscopy and CT scans immediately af-
ter the end of neoadjuvant CRT (C-CRT/S group) or 3 months after 
definitive CRT (CRT group). Treatment-related toxicities were 
scored according to the Common Terminology Criteria for Ad-
verse Events (version 3.0). To assess the prognostic impact of pa-
tient and treatment characteristics, the Cox proportional hazards 
model was used. Factors proven to be of significance (p  ^  0.05) 
were entered into the multivariate analysis. All data were analyzed 
using PASW 18.0 (SPSS Inc., Chicago, Ill., USA).
 Results 
 Patient and Treatment Characteristics 
 Of 129 patients included in this analysis, 78 patients 
(60%) received CRT whereas 51 patients (40%) underwent 
C-CRT/S. Patient demographics are listed in  table 1 . An 
intercohort comparison revealed no relevant differences 
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except for a higher frequency of T4 tumors in the CRT 
group (19 vs. 4%; p = 0.008). Corresponding to the higher 
frequency of obstructive tumors in the CRT group, more 
patients were dependent on feeding tubes before treat-
ment (27 vs. 10%; p = 0.024). The treatment differences 
between the two groups are shown in  table 2 . According 
to the differing treatment intention, patients in the CRT 
group received significantly higher RT doses (median RT 
dose 60.0 vs. 40.0 Gy; p  ! 0.001) and had greater planning 
target volumes (median 842 vs. 706 ml; p  ! 0.001).
 Treatment Performance and Tolerability 
 All patients scheduled for CRT received the RT dose as 
planned. In contrast, chemotherapy had to be modified 
or even aborted in about one third of patients (n = 28) due 
to non-specific deterioration of performance status (n = 
10), hematological toxicity (n = 7) or denial of further 
treatment (n = 8). In the C-CRT/S group, the RT dose was 
limited to 36.0 Gy without chemotherapy due to progres-
sive disease in 1 patient scheduled for 40.0 Gy. With re-
spect to chemotherapy, at least two inductive cycles were 
accomplished by all patients. Grade 3/4 hematological 
side effects required dose reductions during the following 
courses in 9 patients. Five patients proceeded with RT 
alone instead of concomitant CRT due to progressive dis-
ease (n = 2), acute renal failure (n = 1) and hematological 
toxicity (n = 2). Fifty-seven patients (73%) in the CRT 
group and 49 patients (96%) in the C-CRT/S group re-
ceived more than two thirds of the chemotherapy as 
planned ( table 2 ). Among the 51 patients of the C-CRT/S 
group, 28 patients were scheduled for surgery. However, 
at the time of surgery, 9 patients were found to be irresect-
able or showed loss of distant tumor control; the remain-
der (n = 19) received a complete tumor resection (R0).
 With 7 patients being lost by early death or incomplete 
follow-up, 122 patients were assessable for late treatment-
related toxicity ( table 3 ). Of 86 patients who had not re-
ceived a feeding tube before or during treatment, 12 pa-
tients (14%) developed a late tube-dependent dysphagia. 
Repeated balloon dilatation or stenting was necessary in 
33 patients (27%). Tracheoesophageal fistulae occurred in 
19 patients (16%). Five fatal events (4%) were undoubt-
edly related to treatment: 3 patients died of postoperative 
complications following surgery (anastomotic leakage) 
and 2 patients developed a fatal tracheoesophageal fis-
tula (CRT group). The incidence of fatal events did not 
statistically differ between the two treatment groups (p = 
0.66).
 Survival and Tumor Control 
 The median follow-up time for patients alive was 3 
years (36.1 months, range 5.6–124.3).  On intent-to-treat 
analysis of all patients, the median, 2- and 5-year OS 
probability was 17.6 months (95% confidence interval 
13.0–22.0), 42 and 24%, respectively. The 2- and 5-year 
LRC rates were 56 and 50%, respectively, and the actu-
arial DC rates reached 67 and 52%, respectively.
 Comparing the CRT and C-CRT/S groups, there was 
no significant difference in terms of OS (2-year OS 39.1 
vs. 45.1%; p = 0.89) ( fig. 1 a) and DC rates (2-year DC 71.2 
vs. 62.4%; p = 0.091). However, patients in the CRT group 
Table 1.  Patient characteristics
CRT
(n = 78)
C-CRT/S 
(n = 51)
Entire cohort
(n = 129)
Median age, years 63 [43–78] 60 [42–76] 62 [42–78]
Age
≤60 years 32 (41) 24 (47) 56 (43)
>60 years 46 (59) 27 (53) 73 (57)
Gender
Male 68 (87) 43 (84) 111 (86)
Female 10 (13) 8 (16) 18 (14)
Histology
SCC 61 (78) 36 (71) 97 (75)
AC 15 (19) 15 (29) 30 (23)
Missing 2 (3) 2 (2)
Grading
G1 7 (9) 5 (10) 12 (9)
G2 39 (46) 30 (59) 69 (53)
G3 22 (28) 14 (27) 36 (28)
Missing 10 (13) 2 (4) 12 (9)
Primary tumor subsite
Proximal third 19 (24) 9 (18) 28 (22)
Mid third 32 (41) 21 (41) 53 (41)
Distal third 21 (27) 14 (27) 35 (27)
GEJ 6 (8) 7 (14) 13 (10)
Tumor status
Tx (nodal recurrence) 4 (5) 4 (3)
T1 4 (5) 4 (3)
T2 7 (9) 2 (4) 9 (7)
T3 48 (62) 47 (92) 95 (74)
T4 (p = 0.008) 15 (19) 2 (4) 17 (13)
Nodal status
N0 19 (24) 8 (16) 27 (21)
N1 59 (76) 43 (84) 102 (79)
Stage
I/II 23 (29) 10 (20) 33 (26)
III 49 (63) 40 (78) 89 (69)
IVA 6 (8) 1 (2) 7 (5)
F igures in parentheses are percentages; figures in brackets are 
ranges. SCC = Squamous cell carcinoma; AC = adenocarcinoma; 
GEJ = gastroesophageal junction.
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Table 2.  Treatment details
CRT
(n = 78)
C-CRT/S
(n = 51)
Entire cohort
(n = 129)
p
Surgery
None 75 (96) 32 (63) 107 (83)
Preceding CRT 3 (4) 3 (2)
Following C-CRT 19 (37) 19 (15) <0.001
Median RT dose, Gy 60 [50–72] 40 [30–70] 60 [30–72] <0.001
RT dose
<50 Gy 28 (55) 28 (22) <0.001
≥50 Gy 78 (100) 23 (45) 101 (78)
<60 Gy 32 (41) 30 (59) 62 (48) 0.07
≥60 Gy 46 (59) 21 (41) 67 (52)
RT technique
IMRT 22 (28) 1 (2) 23 (18) <0.001
3D conformal 56 (72) 50 (98) 106 (82)
Median PTV, ml 842 [240–2,212] 706 [334–1,529] 788 [240–2,212]
Inductive CT
Yes 8 (10) 51 (100) 59 (46) <0.001
No 70 (90) 70 (54)
Adherence to CT
100% 47 (60) 39 (76) 86 (67) 0.06
<100% 31 (40) 12 (24) 43 (33)
≥ two thirds 57 (73) 49 (96) 106 (82) 0.01
< two thirds 21 (27) 2 (4) 23 (18)
F igures in parentheses are percentages; figures in brackets are ranges. IMRT = Intensity-modulated radiotherapy; PTV = planning 
target volume.
Table 3.  Acute and late toxicity
Acute toxicity CRT (n = 78) C-CRT (n = 51) C-CRT/S (n = 51) p
Hematological grade 3/4 6 (7) 7 (14) 10 (20) <0.001
Non-hematological
Cardiovascular (arrhythmia/general) grade 5 2 (3)
Tracheoesophageal fistula/bleeding grade 5 1 (1)
Anastomotic leakage/aspiration pneumonia grade 5 3 (6)
Acute dysphagia
Pre-existing gastrostomy dependency1 21 (27) 5 (10) 0.024
Esophagitis requiring gastrostomy during treatment2 11/57 (19) 4/46 (9) 2/46 (4) 0.19
Late toxicity CRT (n = 73) C-CRT (n = 49) C-CRT/S (n = 49) p
Late tracheoesophageal fistula 8 (10) 9 (18) 2 (4) 0.077
Late tracheoesophageal fistula/bleeding grade 5 2 (3)
Chronic dysphagia
Esophageal stricture requiring dilatation/stenting 18 (25)                  12 (24) 3 (6) 0.41
Esophageal stricture requiring late gastrostomy2 9/46 (20) 2/40 (5) 1/40 (3) 0.13
F igures in parentheses are percentages.
1 Indicating patients who needed to supplement most of their diet with gastrostomy tube feedings before treatment.
2 Percentages refer to patients at risk. 
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showed significantly better LRC rates (2-year LRC 70.2 
vs. 40.4%; p = 0.003) ( fig. 1 b). In the C-CRT/S group, the 
inclusion of surgery led to significantly improved LRC 
rates (2-year LRC with and without surgery 73.6 vs. 21.2%, 
respectively; p = 0.003); however, this was translated only 
into a trend towards improved OS (2-year OS 63.2 vs. 
34.4%; p = 0.084) ( fig. 2 ). Comparing the surgically re-
sected patients of the C-CRT/S group with all other pa-
tients, a benefit was detectable for both OS and LRC, re-
spectively, but this did not reach statistical significance 
(2-year OS 63.2 vs. 37.5%, p = 0.18; 2-year LRC 73.6 vs. 
52.0%, p = 0.27).
 In the CRT group, patients with T4 tumors or M1a 
stage showed pronouncedly poor LRC and OS rates (2-
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 Fig. 1. Kaplan-Meier curves indicating OS ( a ) and LRC ( b ) stratified for the CRT and the C-CRT/S group
(p values determined by log-rank test). 
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 Fig. 2. Kaplan-Meier curves indicating OS ( a ) and LRC ( b ) in the C-CRT/S group stratified by surgery (p values 
determined by log-rank test). 
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year OS T1–3 vs. T4 43.6 vs. 13.3%; p = 0.003). Accord-
ingly, when excluding those patients, 43.9 and 27.4% 2- 
and 5-year OS rates were reached in the T1–3 N0–1 M0 
subgroup, respectively. With regard to RT doses, all pa-
tients who received  6 60 Gy had better OS and LRC rates 
than those with  ! 60 Gy, without reaching statistical sig-
nificance (p = 0.32 vs. 0.31, respectively). A significant 
improvement in LRC rates by higher RT doses was only 
detectable in the T1–3 N0–1 M0 subgroup (2-year LRC 
77.8 vs. 42.3%; p = 0.036). However, again, this was not 
translated into improved OS (2-year OS 49.0 vs. 32.7%;
p = 0.41) ( fig. 3 ).
 Treatment Outcome and Prognostic Factors 
 One hundred and twenty-four of 129 patients (92%) 
were assessable for treatment response. The overall re-
sponse rate (complete response plus partial response) was 
77%, with almost equal portions of patients achieving 
complete and partial response, respectively. At the time 
of the present analysis, 93 patients of the entire collective 
had died (64% of the CRT group and 84% of the C-CRT/S 
group). Information on tumor control shortly before 
death was available in 90 patients. The majority (81%) had 
died of locoregional or distant tumor progression with a 
significantly higher incidence of both locoregional and 
distant relapses in the C-CRT/S group compared to the 
CRT group (locoregional relapse 59 vs. 23%, p  ! 0.001; 
distant progression 45 vs. 23%, p = 0.017).
 To derive conclusions specific to either CRT or C-
CRT/S, the impact of tumor- and treatment-related fac-
tors was evaluated separately for both treatment groups. 
In CRT patients, the univariate analysis showed the fol-
lowing covariates to be significantly prognostic of OS: tu-
mor grading, T category (T1–3 vs. T4), nodal status, ad-
herence to chemotherapy, and tumor response. Statistical 
significance was maintained multivariately except for the 
nodal status ( table 4 ). In the C-CRT/S group, the tumor 
response was the only statistically significant factor, with 
surgery reaching just borderline significance (p = 0.09). 
Regarding the influence of different RT doses ( ! 60 vs. 
 6 60 and  ! 50 vs.  6 50 Gy in the CRT and C-CRT/S group, 
respectively), unequivocal effects were not detectable.
 Discussion 
 With a 2- and 5-year OS of 42 and 24%, respectively, 
the survival outcome of this unselected population is in 
line with results yielded by large randomized trials on 
definitive CRT or trimodality treatment  [1, 2, 7, 8] . In 
view of the high proportion of advanced disease (87% 
T3/4 tumors) and positive lymph nodes (79%), this result 
is remarkable. In fact, the baseline characteristics of our 
patients were poorer than reported by other institutional 
series  [10–12, 14] . With respect to our CRT group, the OS 
and LRC rates are better than those achieved in the ran-
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 Fig. 3. Kaplan-Meier curves indicating OS ( a ) and LRC ( b ) in the T1–3 N0–1 M0 subgroup of the CRT group 
stratified by RT doses  ! 60.0 and  6 60.0 Gy (p values determined by log-rank test). 
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domized and non-randomized part of the RTOG 8501 
study  [2] . This difference is further extended if one con-
fines the analysis to the RTOG 8501 analog T1–3 N0–1 
M0 patient subgroup which reached a durable 2-year LRC 
rate of 68% corresponding to a 2- and 5-year OS of 44 and 
27%, respectively. Thus, the present review reports a suc-
cessful translation of phase III evidence into daily clinical 
practice. 
 The high rate of adherence to protocol may have influ-
enced the positive outcome of definitive CRT. In fact, full 
completion of therapy is an important endpoint for pa-
tients with esophageal cancer who often interrupt treat-
ment due to toxicity and a worsening performance status. 
Accordingly, in the RTOG 8501 trial, 7% of patients did 
not receive full RT doses, and only 54% of patients com-
pleted all four cycles of chemotherapy  [1] . In contrast, we 
here report complete adherence to RT, with 73% of pa-
tients having tolerated more than two thirds of chemo-
therapy.
 Regarding the impact of escalated RT doses, we found 
an unequivocal effect only on LRC in the T1–3 N0–1 M0 
subgroup (CRT collective). Apart from statistical reasons 
due to the small sample size, this result most probably 
stems from the poor outcome of patients with T4 tumors 
irrespective of RT doses and treatment schedule. In fact, 
a dose-response relationship  1 50 Gy has not been con-
firmed prospectively in esophageal cancer  [6] , and even 
retrospective studies are sparse. Institutional series re-
porting on a dose-response relationship predominantly 
concern the dose range of 30.0–50.0 Gy  [15] . Information 
on doses  1 50.0 Gy is mostly derived from series on radio-
therapy alone or on heterogeneously designed CRT  [14–
18] . Recently, RT doses  1 54.0 Gy have been multivari-
ately identified to impact OS in an unselected study pop-
ulation subjected to definitive CRT mainly based on 
mitomycin C  [14] . However, in the absence of more de-
tailed data on LRC and DC as well as on treatment-relat-
ed toxicity, the issue of RT dose escalation  1 50 Gy needs 
further investigation. To conclude, although affected by 
all the methodological drawbacks of a retrospective insti-
tutional study, our analysis firstly confirms improved 
LRC rates by escalated RT doses  1 50.0 Gy in the context 
of definitive CRT strictly analogized to the RTOG 8501 
trial.
Table 4.  Prognostic factors on OS (CRT group)
Univariate analysis M ultivariate analysis
unadjusted HR p adjusted HR p
Age
≤60 versus >60 years 1.08 (0.62–1.9) 0.78
Gender
Male versus female 0.95 (0.43–2.11) 0.9
Histology
AC versus SCC 0.44 (0.19–1.03) 0.059
Grading
G1/2 versus G3 2.74 (1.3–5.74) 0.008 2.98 (1.24–7.17) 0.015
Tumor stage
T1–2 versus T3 0.32 (0.1–1.06) 0.062
T1–3 versus T4  0.4 (0.22–0.78) 0.005 0.33 (0.14–0.8) 0.014
Nodal status
N0 versus N1 0.43 (0.19–0.95) 0.036 0.38 (0.12–1.23) 0.11
RT dose
≥60 versus <60 Gy 0.76 (0.43–1.32) 0.324
Adherence to CT
<100 versus 100% 2.78 (1.58–4.83) <0.001 3.48 (1.11–10.93) 0.033
< two thirds versus ≥ two thirds 1.89 (1.04–3.43) 0.037 0.42 (0.13–1.34) 0.143
Response
Less than PR versus PR/CR  3.0 (1.56–5.8) 0.001 1.13 (0.41–3.11) 0.82
Less than CR versus CR 7.09 (3.25–15.5) <0.001  5.0 (1.83–13.69) 0.002
Fig ures in parentheses are 95% confidence intervals. AC = Adenocarcinoma; SCC = squamous cell carcinoma; PR = partial remis-
sion; CR = complete remission; HR = hazard ratio (>1 indicative of worse survival).
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 As to trimodality treatment, randomized data have 
shown the positive impact of surgery on LRC in esopha-
geal cancer without translation into improved OS  [7, 8] . 
In the present analysis, these results have been confirmed 
by the comparison of patients treated surgically in the C-
CRT/S group and those treated in analogy to the RTOG 
8501 concept. Within our C-CRT/S cohort, surgery sig-
nificantly improved the LRC rates; however, this could 
not compensate for the pronouncedly poor results of C-
CRT/S patients who were not operated and stopped treat-
ment after insufficient RT doses (median 40.0 Gy). In 
contrast, inferior LRC and DC rates within the C-CRT/S 
group did not lead to inferior OS rates when compared to 
patients subjected to CRT; one possible explanation would 
be the higher amount of non-tumor-related deaths in the 
CRT group. However, beyond doubt, a selection bias re-
sulting from the non-randomized allocation of patients 
to the two individually adapted treatment concepts limits 
final statements. 
 CRT performed in accordance to RTOG 8501 (RT 
dose range 59.4–66.6 Gy) has been compared to CRT plus 
surgery (RT dose range 41.4–50.4 Gy) in one other single 
analysis  [12] . Further available reports are characterized 
by differing radiotherapy schedules  [10, 16] or variable 
chemotherapy regimens with lower cumulative cisplatin 
doses or even without cisplatin  [11, 14, 16] . In conclusion, 
the successful translation of LRC benefits into improved 
OS is a challenge regardless of whether LRC is achieved 
by surgery or high-dose CRT. In this regard, the optimal 
management of treatment-related toxicities and individ-
ual comorbid factors is of high importance.
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